Triple therapy with ribavirin plus sofosbuvir and daclatasvir increases the rate of sustained virologic response (SVR) achievement in patients with hepatitis C virus (HCV) infection complicated by cirrhosis, according to results of a study published in Annals of Medicine and Surgery.
Between February 2018 and June 2019, researchers conducted a retrospective cohort study to assess the effects of triple therapy with ribavirin plus sofosbuvir and daclatasvir on the rate of SVR achievement among patients with HCV infection at 2 tertiary care hospitals in Pakistan.
Among 359 patients included initially included in the study, 201 completed follow-up. Of these patients, 86 had cirrhosis and were included in the final analysis. The mean patient age was 50.6±10.65 years, 56.9% were women, and the mean FibroScan score was 24.20±12.45.
After completing triply therapy, 81 (95.2%) patients achieved a SVR and 5 (5.81%) did not achieve a SVR.
Factors significantly associated with SVR achievement among patients who did vs did not achieve a SVR included no family history of HCV-related hepatocellular carcinoma (n=84 vs n=3; P =.012), higher platelet counts (190.0×1011/units vs 106.8×1011/units; P =.0001), decreased concentrations of total bilirubin (1.02 mg/dL vs 2.74 mg/dL; P =.0001), and increased concentrations of albumin (3.73 g/dL vs 2.68 g/dL; P =.013).
This study was limited by its retrospective design, small sample size, and the number of patients lost to follow-up.
According to the researchers, “…studies with a much larger sample size and prospective study design are recommended to validate [these] results.”
Sheikh NT, Shaukat MT, Hussain A, et al. SVR achievement in triple therapy treated hepatitis C induced cirrhosis: a dual center retrospective cohort study. Ann Med Surg. Published online July 20, 2022. doi:10.1016/j.amsu.2022.104193.